Influenza A/H5N1 virus outbreaks and prepardness to avert flu pandemic;Menace liée au virus influenza A/H5N1 et mise en place de la prévention face à un risque de pandémie de grippe

Annales de Biologie Clinique

Volumn 65, Issue 2, 2007, Pages 125-133

  Haque, A ^a   Lucas, B ^b   Hober, D ^b  

^a CNRS   (France)

^b University Lille   (France)

Author keywords

Hosts' response; Improved vaccination; Influenza A H5N1 virus; Pandemic; Pathogenesis

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

ANIMAL; AVIAN INFLUENZA; BIRD; DISEASE TRANSMISSION; EPIDEMIC; HUMAN; INFLUENZA; INFLUENZA VIRUS A H5N1; REVIEW;

ANIMALS; BIRDS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

ORTHOMYXOVIRIDAE;

EID: 34047181212     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: 10.1684/abc.2007.0042     Document Type: Review

References (30)

1. Normile D. Avian Influenza. Are wild birds to blame ? Science 2005 ; 310 : 426-8.
2. Chen H, Smith GJ, Li KS, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia : implications for pandemic control. Proc Natl Acad Sci USA 2006 ; 103 : 2845-50.
3. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005 ; 352 : 686-91.
4. Rimmelzwaan GF, van Riel D, Baars M, et al. Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts. Am J Pathol 2006 ; 168 : 176-83.
5. Le QM, Kiso M, Someya K, et al. Avian flu : isolation of drug-resistant H5N1 virus. Nature 2005 ; 437 : 1108.
6. Osterholm MT. Preparing for the next pandemic. N Engl J Med 2005 ; 352 : 1839-42.
7. Cheung CY, Poon LL, Lau AS, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses : a mechanism for the unusual severity of human disease ? Lancet 2002 ; 360 : 1831-7.
8. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006 ; 12 : 1203-7.
9. Cyranoski D. Bird flu spreads among Java's pigs. Nature 2005 ; 435 : 390-1.
10. Lewis DB. Avian flu to human influenza. Annu Rev Med 2006 ; 57 : 139-54.
11. Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol 2002 ; 76 : 767-73.
12. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Virol Immunol 2005 ; 18 : 244-51.
13. Watanabe T, Watanabe S, Kida H, Kawaoka Y. Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology 2002 ; 299 : 266-70.
14. Fauci AS. Emerging and re-emerging infectious diseases : influenza as a prototype of the host-pathogen balancing act. Cell 2006; 124: 665-70.
15. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactived split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine : phase 1 randomised trial. Lancet 2006 ; 367 : 1657-64.
16. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine : a phase I randomised controlled trial. Lancet 2006 ; 368 : 991-7.
17. Stephenson I, Zambon MC, Rudin A, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006 ; 80 : 4962-70.
18. Mingxiao M, Ningyi J, Zhenguo W, et al. Construction and immunogenicity of recombinant fowlpox vaccines coexpressing HA of AIV H5N1 and chicken IL18. Vaccine 2006 ; 24 : 4304-11.
19. Turner SJ, Kedzierska K, La Gruta NL, Webby R, Doherty PC. Characterization of CD8+ T cell repertoire diversity and persistence in the influenza A virus model of localized, transient infection. Semin Immunol 2004 ; 16 : 179-84.
20. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999 ; 5 : 1157-63.
21. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine : a potential priming strategy. J Infect Dis 2005 ; 191 : 1210-5.
22. Nabel GJ. Genetic, cellular and immune approaches to disease therapy : past and future. Nat Med 2004 ; 10 : 135-41.
23. Palese P. Making better influenza virus vaccines ? Emerg Infect Dis 2006 ; 12 : 61-5.
24. Hoelscher MA, Garg S, Bangari DS, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006 ; 367 : 475-81.
25. Gao W, Soloff AC, Lu X, et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006 ; 80 : 1959-64.
26. Epstein SL, Kong WP, Misplon JA, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005 ; 23 : 5404-10.
27. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host antiviral cytokine responses. Nat Med 2002 ; 8 : 950-4.
28. Lipatov AS, Andreansky S, Webby RJ, et al. Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice : the role of cytokines and B- and T-cell responses. J Gen Virol 2005 ; 86 : 1121-30.
29. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat : vaccine development for a potential pandemic. Lancet 2004 ; 4 : 499-509.
30. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu : Influenza virus receptor in human airways. Nature 2006; 440: 435-6.